vs
Global Business Travel Group, Inc.（GBTG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Global Business Travel Group, Inc.的季度营收约是Revvity的1.0倍（$792.0M vs $772.1M），Revvity净利率更高（12.7% vs 10.5%，领先2.3%），Global Business Travel Group, Inc.同比增速更快（34.0% vs 5.9%），Revvity自由现金流更多（$161.8M vs $13.0M），过去两年Global Business Travel Group, Inc.的营收复合增速更高（13.9% vs 9.0%）
环球商旅集团（GBTG）是专业的差旅管理服务商，致力于为各类企业及机构提供全链路商务出行解决方案。核心服务涵盖智能线上预订工具、移动端应用、差旅项目管控与咨询、高管专属出行服务、会议活动支持、差旅数据分析以及出行安全保障等，可满足不同规模客户的多元化商务出行管理需求。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GBTG vs RVTY — 直观对比
营收规模更大
GBTG
是对方的1.0倍
$772.1M
营收增速更快
GBTG
高出28.2%
5.9%
净利率更高
RVTY
高出2.3%
10.5%
自由现金流更多
RVTY
多$148.8M
$13.0M
两年增速更快
GBTG
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $792.0M | $772.1M |
| 净利润 | $83.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 3.7% | 14.5% |
| 净利率 | 10.5% | 12.7% |
| 营收同比 | 34.0% | 5.9% |
| 净利润同比 | 692.9% | 3.9% |
| 每股收益（稀释后） | $0.16 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GBTGRVTY
| Q4 25 | $792.0M | $772.1M | ||
| Q3 25 | $674.0M | $698.9M | ||
| Q2 25 | $631.0M | $720.3M | ||
| Q1 25 | $621.0M | $664.8M | ||
| Q4 24 | $591.0M | $729.4M | ||
| Q3 24 | $597.0M | $684.0M | ||
| Q2 24 | $625.0M | $691.7M | ||
| Q1 24 | $610.0M | $649.9M |
净利润GBTGRVTY
| Q4 25 | $83.0M | $98.4M | ||
| Q3 25 | $-62.0M | $46.7M | ||
| Q2 25 | $15.0M | $53.9M | ||
| Q1 25 | $75.0M | $42.2M | ||
| Q4 24 | $-14.0M | $94.6M | ||
| Q3 24 | $-128.0M | $94.4M | ||
| Q2 24 | $27.0M | $55.4M | ||
| Q1 24 | $-19.0M | $26.0M |
毛利率GBTGRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率GBTGRVTY
| Q4 25 | 3.7% | 14.5% | ||
| Q3 25 | 1.8% | 11.7% | ||
| Q2 25 | 5.4% | 12.6% | ||
| Q1 25 | 8.9% | 10.9% | ||
| Q4 24 | 5.1% | 16.3% | ||
| Q3 24 | 4.5% | 14.3% | ||
| Q2 24 | 6.7% | 12.4% | ||
| Q1 24 | 2.6% | 6.8% |
净利率GBTGRVTY
| Q4 25 | 10.5% | 12.7% | ||
| Q3 25 | -9.2% | 6.7% | ||
| Q2 25 | 2.4% | 7.5% | ||
| Q1 25 | 12.1% | 6.4% | ||
| Q4 24 | -2.4% | 13.0% | ||
| Q3 24 | -21.4% | 13.8% | ||
| Q2 24 | 4.3% | 8.0% | ||
| Q1 24 | -3.1% | 4.0% |
每股收益（稀释后）GBTGRVTY
| Q4 25 | $0.16 | $0.86 | ||
| Q3 25 | $-0.13 | $0.40 | ||
| Q2 25 | $0.03 | $0.46 | ||
| Q1 25 | $0.16 | $0.35 | ||
| Q4 24 | $-0.04 | $0.77 | ||
| Q3 24 | $-0.28 | $0.77 | ||
| Q2 24 | $0.06 | $0.45 | ||
| Q1 24 | $-0.04 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $434.0M | $919.9M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $1.6B | $7.3B |
| 总资产 | $4.9B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.88× | — |
8季度趋势，按日历期对齐
现金及短期投资GBTGRVTY
| Q4 25 | $434.0M | $919.9M | ||
| Q3 25 | $427.0M | $931.4M | ||
| Q2 25 | $601.0M | $991.8M | ||
| Q1 25 | $552.0M | $1.1B | ||
| Q4 24 | $536.0M | $1.2B | ||
| Q3 24 | $524.0M | $1.2B | ||
| Q2 24 | $515.0M | $2.0B | ||
| Q1 24 | $475.0M | $1.7B |
总债务GBTGRVTY
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GBTGRVTY
| Q4 25 | $1.6B | $7.3B | ||
| Q3 25 | $1.5B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.1B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $1.2B | $7.9B | ||
| Q1 24 | $1.2B | $7.8B |
总资产GBTGRVTY
| Q4 25 | $4.9B | $12.2B | ||
| Q3 25 | $4.8B | $12.1B | ||
| Q2 25 | $3.9B | $12.4B | ||
| Q1 25 | $3.8B | $12.4B | ||
| Q4 24 | $3.6B | $12.4B | ||
| Q3 24 | $3.8B | $12.8B | ||
| Q2 24 | $3.8B | $13.4B | ||
| Q1 24 | $3.8B | $13.4B |
负债/权益比GBTGRVTY
| Q4 25 | 0.88× | — | ||
| Q3 25 | 0.91× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 1.32× | — | ||
| Q3 24 | 1.26× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $52.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $13.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 1.6% | 21.0% |
| 资本支出强度资本支出/营收 | 4.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 0.63× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $104.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流GBTGRVTY
| Q4 25 | $52.0M | $182.0M | ||
| Q3 25 | $71.0M | $138.5M | ||
| Q2 25 | $57.0M | $134.3M | ||
| Q1 25 | $53.0M | $128.2M | ||
| Q4 24 | $65.0M | $174.2M | ||
| Q3 24 | $85.0M | $147.9M | ||
| Q2 24 | $73.0M | $158.6M | ||
| Q1 24 | $49.0M | $147.6M |
自由现金流GBTGRVTY
| Q4 25 | $13.0M | $161.8M | ||
| Q3 25 | $38.0M | $120.0M | ||
| Q2 25 | $27.0M | $115.5M | ||
| Q1 25 | $26.0M | $112.2M | ||
| Q4 24 | $33.0M | $149.8M | ||
| Q3 24 | $59.0M | $125.6M | ||
| Q2 24 | $49.0M | $136.6M | ||
| Q1 24 | $24.0M | $129.7M |
自由现金流率GBTGRVTY
| Q4 25 | 1.6% | 21.0% | ||
| Q3 25 | 5.6% | 17.2% | ||
| Q2 25 | 4.3% | 16.0% | ||
| Q1 25 | 4.2% | 16.9% | ||
| Q4 24 | 5.6% | 20.5% | ||
| Q3 24 | 9.9% | 18.4% | ||
| Q2 24 | 7.8% | 19.7% | ||
| Q1 24 | 3.9% | 20.0% |
资本支出强度GBTGRVTY
| Q4 25 | 4.9% | 2.6% | ||
| Q3 25 | 4.9% | 2.6% | ||
| Q2 25 | 4.8% | 2.6% | ||
| Q1 25 | 4.3% | 2.4% | ||
| Q4 24 | 5.4% | 3.4% | ||
| Q3 24 | 4.4% | 3.3% | ||
| Q2 24 | 3.8% | 3.2% | ||
| Q1 24 | 4.1% | 2.7% |
现金转化率GBTGRVTY
| Q4 25 | 0.63× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 3.80× | 2.49× | ||
| Q1 25 | 0.71× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 2.70× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GBTG
| Travel | $620.0M | 78% |
| Other | $172.0M | 22% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
